When pharmacovigilance inspections focus on aggregate reporting, regulators are not simply reviewing documents. They are evaluating the maturity of the entire safety surveillance system behind those documents.

A well-written PSUR, PBRER, or DSUR may appear compliant on the surface. However, inspectors increasingly look beyond the final report and examine the processes used to collect data, evaluate signals, assess risks, perform reconciliations, and reach scientific conclusions.

This shift has resulted in a growing number of inspection observations related to aggregate reporting systems.

Many organizations continue to view aggregate reports as periodic regulatory deliverables. Regulators, however, increasingly view them as evidence of how effectively a company understands and manages the safety profile of its products.

As a result, deficiencies in aggregate reporting often trigger broader questions about pharmacovigilance governance, signal management, quality oversight, and inspection readiness.

1. Why Aggregate Reporting Failures Matter So Much

Unlike individual case processing errors, aggregate reporting deficiencies may affect the interpretation of thousands of safety cases simultaneously.

Regulators depend on aggregate reports to understand:

• Emerging safety risks
• Changes in benefit-risk balance
• Signal evaluation outcomes
• Exposure trends
• Risk minimization effectiveness

If aggregate reports contain incomplete, inaccurate, or poorly interpreted information, regulators may be unable to assess the true safety profile of a medicinal product.

This is why deficiencies in aggregate reporting frequently receive significant regulatory attention.

Inspectors often consider aggregate reporting findings as indicators of broader pharmacovigilance system weaknesses.

2. Late Submission of Aggregate Reports

One of the most common aggregate reporting findings worldwide remains late submission.

Organizations often underestimate the complexity involved in preparing PSURs, PBRERs, and DSURs.

Delays commonly occur because of:

• Late reconciliation activities
• Incomplete signal reviews
• Resource shortages
• Poor planning
• Vendor delays
• Governance bottlenecks

Inspectors generally view repeated submission delays as evidence of inadequate planning and oversight.

Organizations with mature reporting systems typically maintain reporting calendars, milestone tracking tools, escalation mechanisms, and management oversight processes.

When timelines are repeatedly missed, regulators often question whether sufficient resources and governance controls exist.

3. Weak Benefit-Risk Evaluation

One of the most significant changes in regulatory expectations involves benefit-risk evaluation.

Historically, many reports focused primarily on summarizing adverse event data.

Modern regulators expect organizations to demonstrate meaningful scientific assessment of whether product benefits continue to outweigh associated risks.

Common deficiencies include:

• Generic conclusions
• Lack of supporting rationale
• Failure to discuss important risks
• Insufficient benefit assessment
• Poor integration of safety findings

Inspectors increasingly review whether benefit-risk conclusions are supported by the underlying data.

Reports containing superficial analysis may raise concerns about the overall quality of safety oversight.

4. Signal Management Deficiencies in Aggregate Reports

Signal management and aggregate reporting are closely connected.

Inspectors frequently compare signal governance documentation with information presented in aggregate reports.

Common deficiencies include:

• Missing signal discussions
• Inconsistent signal status descriptions
• Incomplete signal evaluations
• Failure to document signal outcomes
• Weak scientific justification

For example, a signal reviewed extensively by a safety committee may receive little or no discussion within an aggregate report.

Such inconsistencies often trigger regulatory concern because they suggest weak integration between pharmacovigilance functions.

Organizations must ensure that signal management activities are reflected consistently across all reporting systems.

5. Data Reconciliation Failures

Aggregate reports depend heavily on data from multiple sources.

Common data sources include:

• Safety databases
• Clinical databases
• Literature surveillance systems
• Partner company information
• Exposure data systems

Weak reconciliation processes may result in:

• Missing cases
• Duplicate information
• Incorrect exposure estimates
• Inconsistent metrics
• Conflicting report conclusions

Inspectors increasingly review reconciliation evidence in detail.

Organizations that cannot demonstrate how data was verified may face significant inspection observations.

6. Exposure Estimate Problems

Accurate exposure estimates are essential for meaningful safety assessment.

Without reliable exposure data, organizations cannot properly evaluate reporting rates, trends, or benefit-risk balance.

Common exposure-related deficiencies include:

• Unsupported calculations
• Missing assumptions
• Outdated exposure figures
• Inconsistent methodologies
• Poor documentation

Inspectors frequently request evidence supporting exposure calculations.

Organizations should therefore maintain clear documentation showing how exposure estimates were derived and validated.

7. Poor Cross-Functional Communication

Aggregate reporting depends heavily on collaboration across multiple departments.

Contributors may include:

• Pharmacovigilance
• Medical Affairs
• Clinical Operations
• Regulatory Affairs
• Epidemiology
• Biostatistics
• Quality Assurance

Communication failures frequently result in:

• Missing data
• Inconsistent conclusions
• Delayed reviews
• Version control issues
• Approval bottlenecks

Many inspection findings ultimately trace back to governance and communication weaknesses rather than technical reporting errors.

Strong reporting organizations generally maintain formal governance structures and clearly defined responsibilities.

8. Inadequate Quality Review Processes

Quality review is one of the final opportunities to identify deficiencies before regulatory submission.

Weak review systems often fail to identify:

• Data inconsistencies
• Missing sections
• Scientific inaccuracies
• Formatting issues
• Signal management gaps

Inspectors increasingly evaluate not only whether reviews occurred but also whether reviews were effective.

Organizations should maintain documented review procedures, reviewer qualifications, and quality metrics supporting the effectiveness of the review process.

9. CAPA Failures and Repeat Observations

Many organizations receive the same aggregate reporting findings repeatedly.

This often indicates ineffective CAPA implementation.

Common CAPA-related deficiencies include:

• Superficial root cause analysis
• Poor corrective action planning
• Failure to verify effectiveness
• Inadequate trend analysis
• Limited management oversight

Inspectors increasingly expect organizations to evaluate systemic causes rather than attributing deficiencies solely to human error.

Repeated aggregate reporting failures often indicate deeper operational weaknesses requiring broader remediation efforts.

10. What High-Performing Organizations Do Differently

Organizations that consistently perform well during inspections usually treat aggregate reporting as an ongoing pharmacovigilance activity rather than a periodic documentation exercise.

Successful programs typically include:

• Strong governance structures
• Early planning processes
• Formal reconciliation programs
• Integrated signal management
• Robust quality review systems
• Effective CAPA programs

These organizations maintain visibility into safety trends continuously rather than waiting until report preparation begins.

As regulatory expectations continue evolving, proactive operational oversight will become increasingly important.

FAQs

What is the most common aggregate reporting inspection finding?

Late submissions, weak benefit-risk evaluations, and inadequate signal integration remain among the most common findings.

Why do inspectors review exposure calculations?

Exposure estimates support safety trend analysis and benefit-risk evaluation. Incorrect exposure data may affect regulatory conclusions.

Why is signal management important for aggregate reports?

Aggregate reports must reflect current signal evaluations and demonstrate how safety concerns are being assessed and managed.

Can poor reconciliation lead to inspection findings?

Yes. Weak reconciliation practices may result in incomplete or inaccurate safety assessments and are a common inspection focus area.

Why do aggregate reporting findings often repeat?

Repeated findings usually indicate ineffective CAPA implementation or unresolved systemic operational issues.

Inspection Readiness Notes

• Verify reconciliation evidence for all major data sources.
• Ensure signal governance decisions are reflected consistently in reports.
• Maintain documented rationale supporting benefit-risk conclusions.
• Review exposure estimate methodologies periodically.
• Trend aggregate reporting deviations and CAPA effectiveness continuously.

Regulatory and Authoritative References

• ICH E2C(R2) Periodic Benefit-Risk Evaluation Report Guideline
• ICH E2F Development Safety Update Report Guideline
• EMA Good Pharmacovigilance Practices (GVP)